Additional work to demonstrate the usefulness of patient-derived LCLs to follow the patient response to a particular treatment, as well as to extensively characterize LCLs from patients carrying mutations in TARDBP, Corf72, among other ALS-related genes is underway in our laboratory. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.